Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer

A Finnish Company ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) Have Signed a Contract Manufacturing Agreement to Jointly Market and Sell PDG Granule and Tablet Manufacturing Services for the Pharmaceutical Industry

HELSINKI, Finland, March 4, 2010 - Atacama Labs Oy has developed an innovative oral drug delivery technology
(called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology
is aimed to replace existing solid dosage form development and manufacturing
methods (like wet granulation or standard roller compaction) and will help
both NCE galenic developers and life cycle managers to overcome development
or differentiation issues.

The Excella / Atacama Labs partnership offers a cGMP compliant and FDA /
EMEA / Anvisa certified environment to house Atacama's innovative and fully
automated PDG equipment.

"We can develop almost any API (including difficult ones) into higher
drug load tablets with good hardness and dissolution profiles and our clients
can profit from new tablet characteristics to extend the life cycle of
expiring drugs, which can mean several more years of protected sales of a
blockbuster drug. In both cases, global economics can be hundreds of millions
of additional revenue, naturally subject to magnitude of drug revenue," Mr.
Mittwich, CEO of the Atacama Labs Oy concludes.

Fareva Holding SA : Manufacturing excellence

Excella GmbH is part of FAREVA Holding, one of the top 10 contract
manufacturing organizations in the world. Fareva today is covering services
in four fields - Pharmaceuticals, Cosmetics, Home Care & Industrial and Food.

FAREVA's Pharma Division provides a full service, ranging from
pharmaceutical and chemical development, pilot scale manufacturing, supply of
clinical studies till industrial-scale production, packaging and quality
control. Ten pharmaceutical sites located throughout Europe serve the
customer's needs for practically all marketed dosage forms as well as APIs.

Excella GmbH - located in Nuremberg, Germany - provides Contract
Manufacturing Services, especially for the development, clinical supply and
commercial manufacturing of solid dosage forms specially for cytotoxics, high
potent or other critical actives with low occupational exposure levels.

"Atacama Lab's Pneumatic Dry Granulation or PDG Technology(TM) is
revolutionary in the sense that it offers significant advantages in terms of
API treatability, development speed and costs over today's dry and wet
granulation processes " Dr. Michael Tschope , General Manager Pharma, Excella
GmbH.

About Atacama Labs Oy

Atacama Labs Oy is a privately owned specialty pharmaceutical company
that offers

    - galenic development from test granulations to full galenic development,
      and
    - contract manufacturing services from tablets to fully packaged
      products.

The Company is located in Helsinki, Finland.

www.atacamalabs.com

For further information, please contact: Dr. Michael Tschope , General Manager, Dr. Michael Tschope, General Manager Pharma, Excella GmbH, Tel: +49-9128-404500, mtschoepe at excella-pharma-source.de; Steffen Mittwich, CEO, Atacama Labs Oy, Tel: +41-79-369-3410, steffen.mittwich at atacamalabs.com